fbpx
Instagram Twitter Linkedin-in Youtube
GET IN TOUCH

List – 59 Drug Patents that are Expiring in 2027

Life Sciences

Meet The Authors

A drug used for the treatment of prostate cancer is going off-patent in 2027. Another one, which ministers to Type 2 Diabetes is going off-patent in the same year too. And there are so many more of them, all going off-patent in 2027!

To make your work easy, we collected not just the names of the drug patents expiring in 2027, but also included other information like the yearly sales, treatment, ingredients, and the disease they cure which could help you easily choose the drug most profitable to develop a generic version.

So, without any delay, here is the list of drugs. Thank us later!

The article has a list of drug patents expiring in 2027. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.

Download Drug Patent Expiration Report

Download PDF

Download Drug Patent Expiration Report

Fill out the form to get access to the list:​

Procysbi

Cysteamine

PatentsExpiration Date
US9925158January 26, 2027
US9925157January 26, 2027
US9925156January 26, 2027

Dosage: Oral, Eye drops
Company: Horizon Therapeutics plc
Ingredients: CYSTEAMINE BITARTRATE
Treatment: Cystinosis

Ongentys

Opicapone

PatentsExpiration Date
US8907099May 12, 2027
US8168793April 2, 2029
US9630955December 12, 2032

Dosage: Oral
Company: Neurocrine Biosciences, Inc
Ingredients: OPICAPONE
Treatment: Parkinson’s Disease

Iclusig

Ponatinib

PatentsExpiration Date
US8114874January 24, 2027
US9493470December 12, 2033
US11192897December 12, 2033

Dosage: Oral
Company: Takeda Pharmaceuticals
Ingredients: PONATINIB HYDROCHLORIDE
Treatment: Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive (Ph+), Acute Lymphoblastic Leukemia (ALL).

Ovide

Malathion

PatentsExpiration Date
US7560445February 1, 2027

Dosage: Topical
Company: Taro Pharmaceuticals
Ingredients: MALATHION
Treatment: Pediculosis

Altabax

Retapamulin

PatentsExpiration Date
US7875630February 14, 2027

Dosage: Topical
Company: GlaxoSmithKline
Ingredients: RETAPAMULIN
Treatment: Impetigo

Stribild

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil

PatentsExpiration Date
US7176220February 27, 2027
US7635704April 26, 2027
US8981103April 26, 2027

Dosage: Oral
Company: Gilead Sciences Inc
Ingredients: COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Treatment: HIV/AIDS

Altabax

Retapamulin

PatentsExpiration Date
US7176220February 27, 2027
US7635704April 26, 2027
US8981103April 26, 2027

Dosage: Oral
Company: Wyeth Pharmaceuticals Llc
Ingredients: BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
Treatment: Hot Flashes, Osteoporosis

Stribild

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil

PatentsExpiration Date
US7176220February 27, 2027
US7635704April 26, 2027
US8981103April 26, 2027

Dosage: Oral
Company: Gilead Sciences Inc
Ingredients: COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Treatment: HIV/AIDS

Duavee

Conjugated Estrogens/Bazedoxifene

PatentsExpiration Date
US7683051March 10, 2027

Dosage: Oral
Company: Wyeth Pharmaceuticals Llc
Ingredients: BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
Treatment: Hot Flashes, Osteoporosis

Zolinza

Vorinostat

PatentsExpiration Date
US7456219March 11, 2027

Dosage: Oral
Company: Merck & Co
Ingredients: VORINOSTAT
Treatment: Cutaneous T Cell Lymphoma (CTCL)

Erleada

Apalutamide

PatentsExpiration Date
US9388159March 27, 2027
US8445507September 15, 2030
US9481663June 4, 2033

Dosage: Oral
Company: Janssen-Cilag International NV
Ingredients: APALUTAMIDE
Treatment: Prostate Cancer

Varubi

Rolapitant

PatentsExpiration Date
US8178550April 4, 2027
US7049320August 19, 2028

Dosage: Oral
Company: Tesaro
Ingredients: ROLAPITANT HYDROCHLORIDE
Treatment: Chemotherapy-induced Nausea And Vomiting (CINV)

Symdeko

Tezacaftor-ivacaftor

PatentsExpiration Date
US10239867April 9, 2027
US8623905May 1, 2027
US7645789May 1, 2027
US7776905June 3, 2027

Dosage: Oral
Company: Vertex Pharmaceuticals Inc
Ingredients: IVACAFTOR; IVACAFTOR, TEZACAFTOR
Treatment: Cystic Fibrosis

Synjardy

Empagliflozin/Metformin

PatentsExpiration Date
US7713938April 15, 2027
US7579449August 1, 2028

Dosage: Oral
Company: Boehringer Ingelheim/Eli Lilly And Company
Ingredients: EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Treatment: Type 2 Diabetes

Savaysa

Edoxaban

PatentsExpiration Date
US7365205April 18, 2027

Dosage: Oral
Company: Daiichi Sankyo
Ingredients: EDOXABAN TOSYLATE
Treatment: Venous Thromboembolism

Amyvid

Florbetapir (18f)

PatentsExpiration Date
US8506929April 30, 2027
US7687052April 30, 2027

Dosage: Intravenous Injection
Company: Avid Radiopharmaceuticals
Ingredients: FLORBETAPIR F-18
Treatment: Alzheimer’s

Mekinist

Trametinib

PatentsExpiration Date
US7378423May 29, 2027

Dosage: Oral
Company: Novartis
Ingredients: TRAMETINIB DIMETHYL SULFOXIDE
Treatment: Melanoma

Altavera/Alysena/Amethyst

Ethinylestradiol/Levonorgestrel

PatentsExpiration Date
US7838042June 1, 2027

Dosage: Oral
Company: Bayer Healthcare Pharmaceuticals
Ingredients: ETHINYL ESTRADIOL; LEVONORGESTREL
Treatment: Contraception

Xadago

Safinamide

PatentsExpiration Date
US8278485June 8, 2027
US8076515December 10, 2028

Dosage: Oral
Company: Newron Pharmaceuticals
Ingredients: SAFINAMIDE MESYLATE
Treatment: Parkinson’s Disease

Xadago

Safinamide

PatentsExpiration Date
US8278485June 8, 2027
US8076515December 10, 2028

Dosage: Oral
Company: Newron Pharmaceuticals
Ingredients: SAFINAMIDE MESYLATE
Treatment: Parkinson’s Disease

Antizol

Fomepizole

PatentsExpiration Date
US7553863June 30, 2027

Dosage: Intravenous
Company: Paladin Labs
Ingredients: FOMEPIZOLE
Treatment: Ethylene Glycol And Methanol Poisoning

Vokanamet

Canagliflozin/Metformin

PatentsExpiration Date
US7943788July 14, 2027
US8513202December 3, 2027
US7943582February 26, 2029

Dosage: Intravenous
Company: Janssen-cilag International Nv
Ingredients: CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Treatment: Type 2 Diabetes

Asacol/Lialda/Pentasa

Mesalazine

PatentsExpiration Date
US7645801July 24, 2027

Dosage: Oral, Rectal
Company: Tillotts Pharma Ag.
Ingredients: MESALAMINE
Treatment: Ulcerative Colitis And Crohn’s Disease

Daklinza

Daclatasvir

PatentsExpiration Date
US9421192August 8, 2027
US8642025August 11, 2027
US8329159July 24, 2029
US8629171June 13, 2031

Dosage: Oral
Company: Bristol-Myers Squibb
Ingredients: DACLATASVIR DIHYDROCHLORIDE
Treatment: Hepatitis C

Xtandi

Enzalutamide

PatentsExpiration Date
US7709517August 13, 2027

Dosage: Oral
Company: Astellas Pharma Inc.
Ingredients: ENZALUTAMIDE
Treatment: Prostate Cancer

Azilect

Rasagiline

PatentsExpiration Date
US7815942August 27, 2027

Dosage: Oral
Company: Teva Pharmaceutical
Ingredients: RASAGILINE MESYLATE
Treatment: Parkinson’s Disease

Tivicay

Dolutegravir

PatentsExpiration Date
US8129385October 5, 2027
US9242986December 8, 2029
US10426780January 24, 2031

Dosage: Oral
Company: Viiv Healthcare
Ingredients: DOLUTEGRAVIR SODIUM
Treatment: HIV/AIDS

Imcivree

Setmelanotide

PatentsExpiration Date
US9458195October 13, 2027
US8039435October 13, 2027

Dosage: Subcutaneous
Company: Rhythm Pharmaceutical
Ingredients: SETMELANOTIDE ACETATE
Treatment: Genetic Obesity

Xcopri

Cenobamate

PatentsExpiration Date
US7598279October 30, 2027

Dosage: Subcutaneous
Company: SK Biopharmaceuticals
Ingredients: CENOBAMATE
Treatment: Partial Epilepsies

Pylarify

Piflufolastat F-18

PatentsExpiration Date
US10793596November 12, 2027
US10017536November 12, 2027
US8536131November 12, 2027
US7727963November 12, 2027
US7713937November 12, 2027
US7402564November 12, 2027

Dosage: Intravenous
Company: Progenics Pharmaceuticals
Ingredients: PIFLUFOLASTAT F-18
Treatment: Prostate Cancer Metastasis

Korsuva

Difelikefalin

PatentsExpiration Date
US8487129November 7, 2027
US9861713July 31, 2029
US8778305September 21, 2030
US10947197June 9, 2037

Dosage: Intravenous
Company: Cara Therapeutics
Ingredients: DIFELIKEFALIN ACETATE
Treatment: Itching

Empaveli

Pegcetacoplan

PatentsExpiration Date
US9169307November 18, 2027
US7989589December 4, 2027
US7888323December 4, 2027
US10125171August 2, 2033
US10875893November 15, 2033
US10035822November 15, 2033

Dosage: Subcutaneous
Company: Apellis Pharmaceuticals/Swedish Orphan Biovitrum
Ingredients: PEGCETACOPLAN
Treatment: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Tabrecta

Capmatinib

PatentsExpiration Date
US8461330November 19, 2027
US7767675November 19, 2027
US8420645June 5, 2031
US10596178July 22, 2035

Dosage: Subcutaneous
Company: Novartis Pharmaceuticals
Ingredients: CAPMATINIB HYDROCHLORIDE
Treatment: Non-small Cell Lung Cancer (NSCLC)

Turalio

Pexidartinib

PatentsExpiration Date
US9169250November 21, 2027
US8404700November 21, 2027
US8722702November 21, 2027
US7893075October 13, 2028
US10730876May 5, 2036
US9802932May 5, 2036

Dosage: Subcutaneous
Company: Daiichi Sankyo Company
Ingredients: PEXIDARTINIB HYDROCHLORIDE
Treatment: Tenosynovial Giant Cell Tumor (TGCT)

Toradol/Biorolac

Ketorolac

PatentsExpiration Date
US8008338November 24, 2027
US7842714August 15, 2029

Dosage: Oral, Intramuscular, Intravenous, Eye drops, Nasal spray
Company: Cadila Healthcare Limited
Ingredients: KETOROLAC TROMETHAMINE
Treatment: Pain

Entresto

Sacubitril/Valsartan

PatentsExpiration Date
US8877938November 27, 2027

Dosage: Oral
Company: Novartis
Ingredients: SACUBITRIL; VALSARTAN
Treatment: Heart Failure

Xermelo

Telotristat Ethyl

PatentsExpiration Date
US7709493December 11, 2027
US7553840December 11, 2027
US8193204February 27, 2031

Dosage: Oral
Company: Lexicon Pharmaceuticals 
Ingredients: TELOTRISTAT ETIPRATE
Treatment: Carcinoid Syndrome Diarrhea

Jakafi

Ruxolitinib

PatentsExpiration Date
US8415362December 24, 2027
US7598257December 24, 2027
US8722693June 12, 2028

Dosage: Oral, Topical
Company: Incyte Corp/Novartis
Ingredients: RUXOLITINIB PHOSPHATE
Treatment: Myelofibrosis

Nexavar

Sorafenib

PatentsExpiration Date
US8877933December 24, 2027

Dosage: Oral, Topical
Company: Bayer/Onyx Pharmaceuticals
Ingredients: SORAFENIB TOSYLATE
Treatment: Renal Cell Carcinoma

Share This Article:

Table of Contents

Related Articles

More Curated Insights For You

Why Keeping a track of reassignments in your domain is important?

Patent transactions in a domain can reveal many overlooked insights — Insights that your competitors might not be paying attention to when crafting their research and development strategies, or when

READ MORE
GreyB’s CompInsight Perform Competitor Research In 30 Seconds

Perform Competitor Research In 30 Seconds – GreyB’ CompInsight

Have you considered that by solely performing competitor research based on their online presence and ranking, you miss many innovative companies working on similar technologies?  These companies may have even

READ MORE

Our Experience: Common Problems for Patent Review Boards and Our Processes for Solving Them

Especially at young, fast-growing companies, few employees are under more pressure than members of the Patent Review Board, or PRB—also known as a Patent Review Committee. Generally composed of scientists

READ MORE

Five Technologies That Can Disrupt Rocket Propulsion System

Since 1903 when Konstantin Tsiolkovsky proposed the idea of space exploration, and Dr. Robert Goddard made a rocket fly using liquid propellant on March 16, 1926, we’ve witnessed tremendous advances

READ MORE

Track recent patent assignments using GreyB’s assignment tracker

This assignment tracker helps you keep a track of recent assignment/reassignment activities happening in the US. The list provides the top 50 most recent patent assignments registered in the US

READ MORE
Nutraceutical Innovation: Cutting Edge Development in Supplements

8 Nutraceutical Companies and Startups Revolutionizing Food Tech

Nutraceuticals are becoming increasingly popular due to the growing demand for natural and organic products that support health and wellness. Evidently, in 2021, the global nutraceuticals market was valued at

READ MORE

Facing A Roadblock On Your Project?

Our Experts Are Here To Help.

Project Queries

Deepak Syal (Director)

+91-8297806050
Chakshu Kalra (Director)
+91-9878481471
United States
+1-202-455-5058
Singapore
+65 84306322